Publications

2025

• Simon C Mendelsohn, Humphrey Mulenga, Michele Tameris, Tumelo Moloantoa, Stephanus T Malherbe, Austin Katona, Fernanda Maruri, Firdows Noor, Ravindre Panchia, Khuthadzo Hlongwane, Kim Stanley, Yuri F van der Heijden, Katie Hadley, Dominique T Ariefdien, Novel N Chegou, Gerhard Walzl, Thomas J Scriba, Timothy R Sterling, Mark Hatherill, the RePORT South Africa Study Team. Res Sq [Preprint] 2025 Jan 20. Screening for Asymptomatic Tuberculosis among Adults with Household Exposure to a Patient with Pulmonary Tuberculosis.
• Nogueira BMF, Rangel F, Andrade AMS, Daniel EA, Figueiredo MC, Staats C, Rolla VC, Kritski AL, Cordeiro-Santos M, Gupta A, Hanna LE, Sterling TR, Araújo-Pereira M, Andrade BB; RePORT Brazil and RePORT India Consortia. Predictive Markers of Incident Tuberculosis in Close Contacts in Brazil and India. J Infect Dis. 2025 Jan 7:jiae642. doi: 10.1093/infdis/jiae642. Epub ahead of print. PMID: 39763217.
• Mapamba DA, Sabi I, Lalashowi J, Sauli E, Buza J, Olomi W, Mtafya B, Kibona M, Bakuli A, Rachow A, Velen K, Hoelscher M, Ntinginya NE, Charalambous S, Churchyard G, Wallis RS; TB SEQUEL consortium. N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis. J Infect. 2025 Jan 3;90(2):106379. doi: 10.1016/j.jinf.2024.106379. Epub ahead of print. PMID: 39756697.
• Sumner T, Clark RA, Prys-Jones TO, Bakker R, Churchyard G, White RG. The potential impact of new tuberculosis vaccines on the burden of tuberculosis in people with HIV in South Africa. AIDS. 2025 Feb 1;39(2):175-183. doi: 10.1097/QAD.0000000000004038. Epub 2024 Oct 10. PMID: 39411889; PMCID: PMC11676631.

2024

 

• Chihota V, Gombe M, Gupta A, Salazar-Austin N, Ryckman T, Hoffmann CJ, LaCourse S, Mathad JS, Mave V, Dooley KE, Chaisson RE, Churchyard G. Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review. Drugs. 2024 Dec 28. doi: 10.1007/s40265-024-02131-3. Epub ahead of print. PMID: 39733063.
• Sekaggya-Wiltshire C, Mbabazi I, Nabisere RM, Alinaitwe L, Otaalo B, Aber F, Nampala J, Owori R, Bayigga J, Mayito J, Banturaki G, Laker EAO, Castelnuovo B, Sekadde MP, Pasipanodya J, Dooley KE, Stavia T, Zawedde-Muyanja S. Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol. BMJ Open. 2024 Dec 31;14(12):e088389. doi: 10.1136/bmjopen-2024-088389. PMID: 39740953; PMCID: PMC11749192.
• Mabry CJ, Weindel CG, Stranahan LW, VanPortfliet JJ, Davis JR, Martinez EL, West AP, Patrick KL, Watson RO. Necrosis drives susceptibility to Mycobacterium tuberculosis in PolgD257A mutator mice. bioRxiv [Preprint]. 2024 Dec 2:2024.07.17.603991. doi: 10.1101/2024.07.17.603991. PMID: 39091776; PMCID: PMC11291070.
• Pelzer PT, Stuck L, Martinez L, Richards AS, Acuña-Villaorduña C, Aronson NE, Bonnet M, Carvalho AC, Chan PC, Huang LM, Fang CT, Churchyard G, Corral-Londoño HD, Datta M, Espinal MA, Fielding K, Fiore-Gartland AJ, Garcia-Basteiro A, Hanekom W, Hatherill M, Hill PC, Huerga H, Jones-López EC, Kritski A, Mandalakas AM, Mangtani P, Martins Netto E, Mayanja H, Mazahir R, Murray M, Rangaka M, Scriba T, Singh J, Singh S, Stein CM, Vekemans J, Verhagen LM, Villalba JA, Wajja A, Watson B, White RG, Cobelens FGJ. Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data. Lancet Microbe. 2024 Dec 19:100961. doi: 10.1016/j.lanmic.2024.100961. Epub ahead of print. PMID: 39709975.
• Salazar-Austin N, Bergman AJ, Mulder C, Tudor C, Mulatu F, Conradie G, Chaisson RE, Golub JE, Churchyard G, Bedru A, Kerrigan D. Improving access to tuberculosis preventive treatment for children in Ethiopia: designing a home-based contact management intervention for the CHIP-TB trial through formative research. BMC Health Serv Res. 2024 Sep 10;24(1):1043. doi: 10.1186/s12913-024-11451-9. PMID: 39252005; PMCID: PMC11386379.
• Wallis RS, Sabi I, Lalashowi J, Bakuli A, Mapamba D, Olomi W, Siyame E, Ngaraguza B, Chimbe O, Charalambous S, Rachow A, Ivanova O, Zurba L, Myombe B, Kunambi R, Hoelscher M, Ntinginya N, Churchyard G. Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis. NEJM Evid. 2024 Sep;3(9):EVIDoa2300332. doi: 10.1056/EVIDoa2300332. Epub 2024 Aug 27. PMID: 39189858.
• Cumming BM, Addicott KW, Maruri F, Pillay V, Asmal R, Moodley S, Barreto-Durate B, Araújo-Pereira M, Mazibuko M, Mhlane Z, Mbatha N, Khan K, Makhari S, Karim F, Peetluk L, Pym AS, Moosa MYS, van der Heijden YF, Sterling TS, Andrade BB, Leslie A, Steyn AJC. Longitudinal mitochondrial bioenergetic signatures of blood monocytes and lymphocytes improve during treatment of drug-susceptible pulmonary tuberculosis patients. Front Immunol. 2024 Nov 13;15:1465448. doi: 10.3389/fimmu.2024.1465448. PMID: 39606220; PMCID: PMC11599235.
• Klopper M, van der Merwe CJ, van der Heijden YF, Folkerts M, Loubser J, Streicher EM, Mekler K, Hayes C, Engelthaler DM, Metcalfe JZ, Warren RM. The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa. Ann Am Thorac Soc. 2024 Oct;21(10):1391-1397. doi: 10.1513/AnnalsATS.202312-1076OC. PMID: 38935769; PMCID: PMC11451881.
• Maputla SP, Joubert A, Castel S, van der Merwe M, Zangenberg E, Wasserman S, Dooley KE, Wiesner L. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous analysis of isoniazid and pyrazinamide in cerebrospinal fluid. J Pharm Biomed Anal. 2024 Dec 4;255:116613. doi: 10.1016/j.jpba.2024.116613. Epub ahead of print. PMID: 39653626.
• Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM; AIDS Clinical Trial Group; Tuberculosis Trials Consortium. Risk-stratified treatment for drug-susceptible pulmonary tuberculosis. Nat Commun. 2024 Oct 30;15(1):9400. doi: 10.1038/s41467-024-53273-7. PMID: 39477924; PMCID: PMC11526018.
• Wasserman S, Donovan J, Kestelyn E, Watson JA, Aarnoutse RE, Barnacle JR, Boulware DR, Chow FC, Cresswell FV, Davis AG, Dooley KE, Figaji AA, Gibb DM, Huynh J, Imran D, Marais S, Meya DB, Misra UK, Modi M, Raberahona M, Ganiem AR, Rohlwink UK, Ruslami R, Seddon JA, Skolimowska KH, Solomons RS, Stek CJ, Thuong NTT, van Crevel R, Whitaker C, Thwaites GE, Wilkinson RJ. Advancing the chemotherapy of tuberculous meningitis: a consensus view. Lancet Infect Dis. 2025 Jan;25(1):e47-e58. doi: 10.1016/S1473-3099(24)00512-7. Epub 2024 Sep 26. Erratum in: Lancet Infect Dis. 2025 Jan;25(1):e13. doi: 10.1016/S1473-3099(24)00829-6. PMID: 39342951; PMCID: PMC7616680.
• Daniel BD, Selladurai E, Balaji S, Venkatesan A, Venkatesan M, Giridharan P, Shanmugam S, Natrajan S, Karunaianantham R, Kandasamy D, Subramani R, Muthuramalingam K, Pramila SK, Hissar S, Dooley KE, Thakur KT. Clinical and diagnostic features of central nervous system tuberculosis in Indian children - a descriptive study. Ther Adv Infect Dis. 2024 Sep 12;11:20499361241274251. doi: 10.1177/20499361241274251. PMID: 39290458; PMCID: PMC11406600.
• Goletti D, Meintjes G, Andrade BB, Zumla A, Shan Lee S. Insights from the 2024 WHO Global Tuberculosis Report - More Comprehensive Action, Innovation, and Investments required for achieving WHO End TB goals. Int J Infect Dis. 2025 Jan;150:107325. doi: 10.1016/j.ijid.2024.107325. Epub 2024 Dec 2. PMID: 39631498.
• Ridolfi F, Amorim G, Haas DW, Arriaga M, Staats C, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Andrade BB, Sterling TR, Rolla VC; Regional Prospective Observational Research in Tuberculosis Brazil consortium (RePORT-Brazil). Pharmacogenomic associations with HIV-1 virologic suppression in TB/HIV patients. Res Sq [Preprint]. 2024 Dec 16:rs.3.rs-5418156. doi: 10.21203/rs.3.rs-5418156/v1. PMID: 39764089; PMCID: PMC11702782.
• Amorim G, Jaworski J, Yang J, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Turner M, Andrade BB, Velez Edwards DR, Santos AR, Rolla VC, Sterling TR, Haas DW; Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil network. Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort. Pharmacogenet Genomics. 2025 Feb 1;35(2):55-64. doi: 10.1097/FPC.0000000000000552. Epub 2024 Oct 15. PMID: 39470346; PMCID: PMC11695165.
• Amorim G, Haas DW, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Staats C, Hachey B, Turner M, Andrade BB, Rolla VC, Sterling TR; Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil network. Estimating optimal therapeutic drug levels of anti-tuberculosis medications based on treatment safety and effectiveness. medRxiv [Preprint]. 2024 Aug 31:2024.08.30.24312723. doi: 10.1101/2024.08.30.24312723. PMID: 39252925; PMCID: PMC11383476.
• Piekos JA, Amorim G, Ridolfi F, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Andrade BB, Santos AR, Haas DW, Sterling TR, Rolla VC, Edwards DRV; Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil consortium. Genetic ancestry proportion influences risk of adverse events from tuberculosis treatment in Brazil. medRxiv [Preprint]. 2024 Aug 30:2024.08.29.24312595. doi: 10.1101/2024.08.29.24312595. PMID: 39252933; PMCID: PMC11383467.
• Barreto-Duarte B, Villalva-Serra K, Miguez-Pinto JP, Araújo-Pereira M, Campos VMS, Rosier G, Nogueira BMF, Queiroz ATL, Rolla VC, Cordeiro-Santos M, Kritski AL, Martinez L, Rebeiro PF, Sterling TR, Rodrigues MM, Andrade BB. Retreatment and Anti-tuberculosis Therapy Outcomes in Brazil Between 2015 and 2022: A Nationwide Study. Open Forum Infect Dis. 2024 Jul 18;11(8):ofae416. doi: 10.1093/ofid/ofae416. PMID: 39100532; PMCID: PMC11297487.
• Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 1;102(8):600-607. doi: 10.2471/BLT.24.291881. Epub 2024 May 28. PMID: 39070602; PMCID: PMC11276158.
• Auld SC, Queiroz ATL, Araujo-Pereira M, Maenetje P, Mofokeng N, Mngomezulu L, Masilela D, Dobosh B, Tirouvanziam R, Kornfeld H, Andrade BB, Bisson GP. Inflammatory profiles in sputum and blood of people with TB with and without HIV coinfection. medRxiv [Preprint]. 2024 Apr 24:2024.04.23.24306127. doi: 10.1101/2024.04.23.24306127. PMID: 38712023; PMCID: PMC11071534.
• Rodrigues MMS, Barreto-Duarte B, Vinhaes CL, Araújo-Pereira M, Fukutani ER, Bergamaschi KB, Kristki A, Cordeiro-Santos M, Rolla VC, Sterling TR, Queiroz ATL, Andrade BB. Machine learning algorithms using national registry data to predict loss to follow-up during tuberculosis treatment. BMC Public Health. 2024 May 23;24(1):1385. doi: 10.1186/s12889-024-18815-0. PMID: 38783264; PMCID: PMC11112756.
• Xavier MS, Araujo-Pereira M, de Oliveira QM, Sant'Anna FM, Ridolfi FM, de Andrade AMS, Figueiredo MC, Sterling TR, Gordhan BG, Kana BD, Andrade BB, Rolla VC, Gomes-Silva A. The effect of previous SARS-CoV-2 infection on systemic immune responses in individuals with tuberculosis. Front Immunol. 2024 Jun 27;15:1357360. doi: 10.3389/fimmu.2024.1357360. PMID: 38994357; PMCID: PMC11236595.
• Villalva-Serra K, Barreto-Duarte B, Miguez-Pinto JP, Queiroz ATL, Rodrigues MM, Rebeiro PF, Amorim G, Cordeiro-Santos M, Sterling TR, Araújo-Pereira M, Andrade BB. Impact of Xpert MTB/RIF implementation in tuberculosis case detection and control in Brazil: a nationwide intervention time-series analysis (2011-2022). Lancet Reg Health Am. 2024 Jun 5;36:100804. doi: 10.1016/j.lana.2024.100804. PMID: 38912329; PMCID: PMC11192787.
• Arriaga MB, Amorim G, Figueiredo MC, Staats C, Kritski AL, Cordeiro-Santos M, Rolla VC, Andrade BB, Sterling TR; RePORT-Brazil consortia. Effect of Smoking on Longitudinal Interferon-ϒ Release Assay Results among Close Contacts of People with Pulmonary Tuberculosis. J Infect Dis. 2024 May 31:jiae285. doi: 10.1093/infdis/jiae285. Epub ahead of print. PMID: 38820119.
• Xu AY, Velásquez GE, Zhang N, Chang VK, Phillips PPJ, Nahid P, Dorman SE, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Brown NE, Engle ML, Nhung NV, Nsubuga P, Diacon A, Dooley KE, Chaisson RE, Swindells S, Savic RM. Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial. Am J Respir Crit Care Med. 2024 Dec 1;210(11):1358-1369. doi: 10.1164/rccm.202401-0165OC. PMID: 39012226; PMCID: PMC11622436.
• Mendelsohn SC, Andrade BB, Mbandi SK, Andrade AMS, Muwanga VM, Figueiredo MC, Erasmus M, Rolla VC, Thami PK, Cordeiro-Santos M, Penn-Nicholson A, Kritski AL, Hatherill M, Sterling TR, Scriba TJ; RePORT-South Africa and RePORT-Brazil Consortia. Transcriptomic signatures of progression to TB disease among close contacts in Brazil. J Infect Dis. 2024 May 6:jiae237. doi: 10.1093/infdis/jiae237. Epub ahead of print. PMID: 38709708.
• Geiger K, Patil A, Budhathoki C, Dooley KE, Lowensen K, Ndjeka N, Ngozo J, Farley JE. Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes. PLOS Glob Public Health. 2024 May 6;4(5):e0002714. doi: 10.1371/journal.pgph.0002714. PMID: 38709764; PMCID: PMC11073678.
• Moro RN, Mehaffy C, De P, Phillips E, Borisov AS, Sterling TR, Dobos KM. Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection. J Infect Dis. 2024 Nov 15;230(5):1271-1278. doi: 10.1093/infdis/jiae180. PMID: 38640958; PMCID: PMC11489317.
• Gausi K, Ignatius EH, De Jager V, Upton C, Kim S, McKhann A, Moran L, Wiesner L, von Groote-Bidlingmaier F, Marzinek P, Vanker N, Yvetot J, Pierre S, Rosenkranz SL, Swindells S, Diacon AH, Nuermberger EL, Denti P, Dooley KE. High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. Am J Respir Crit Care Med. 2024 Aug 1;210(3):343-351. doi: 10.1164/rccm.202311-2004OC. PMID: 38564365; PMCID: PMC11348975.
• Eke AC, Brummel SS, Aliyu MH, Stranix-Chibanda L, Eleje GU, Ezebialu IU, Korutaro V, Wabwire D, Matubu A, Mbengeranwa T, Chakhtoura N, Chinula L, McCarthy K, Knowles K, Krotje C, Linton MF, Dooley KE, Sax PE, Brown T, Lockman S; IMPAACT 2010/VESTED Study Team. Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy. Clin Infect Dis. 2024 Sep 2:ciae441. doi: 10.1093/cid/ciae441. Epub ahead of print. PMID: 39219495.
• Passos BBS, Araújo-Pereira M, Vinhaes CL, Amaral EP, Andrade BB. The role of ESAT-6 in tuberculosis immunopathology. Front Immunol. 2024 Apr 3;15:1383098. doi: 10.3389/fimmu.2024.1383098. PMID: 38633252; PMCID: PMC11021698.
• Ayers T, Hill AN, Raykin J, Mohanty S, Belknap RW, Brostrom R, Khurana R, Lauzardo M, Miller TL, Narita M, Pettit AC, Pyan A, Salcedo KL, Polony A, Flood J; CDC Tuberculosis Epidemiologic Studies Consortium. Comparison of Tuberculin Skin Testing and Interferon-γ Release Assays in Predicting Tuberculosis Disease. JAMA Netw Open. 2024 Apr 1;7(4):e244769. doi: 10.1001/jamanetworkopen.2024.4769. Erratum in: JAMA Netw Open. 2024 May 1;7(5):e2417484. PMID: 38568690; PMCID: PMC10993073.
• Boyles T, Berhanu RH, Gogela N, Gunter H, Lovelock T, Mphothulo N, Parker A, Rabie H, Richards L, Sinxadi P, Wattrus C, Moosa MY. Management of drug-induced liver injury in people with HIV treated for tuberculosis: 2024 update. South Afr J HIV Med. 2024 Mar 30;25(1):1558. doi: 10.4102/sajhivmed.v25i1.1558. PMID: 38628909; PMCID: PMC11019071.
• Dheda K, Mirzayev F, Cirillo DM, Udwadia Z, Dooley KE, Chang KC, Omar SV, Reuter A, Perumal T, Horsburgh CR Jr, Murray M, Lange C. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024 Mar 24;10(1):22. doi: 10.1038/s41572-024-00504-2. PMID: 38523140.
• Ngo HX, Xu AY, Velásquez GE, Zhang N, Chang VK, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Weiner M, Dooley KE, Engle M, Dorman SE, Nahid P, Swindells S, Chaisson RE, Nsubuga P, Lourens M, Dawson R, Savic RM. Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. Clin Infect Dis. 2024 Jun 14;78(6):1680-1689. doi: 10.1093/cid/ciae119. PMID: 38462673; PMCID: PMC11175687.
• Vinhaes CL, Fukutani ER, Santana GC, Arriaga MB, Barreto-Duarte B, Araújo-Pereira M, Maggitti-Bezerril M, Andrade AMS, Figueiredo MC, Milne GL, Rolla VC, Kristki AL, Cordeiro-Santos M, Sterling TR, Andrade BB, Queiroz ATL; RePORT Brazil Consortium. An integrative multi-omics approach to characterize interactions between tuberculosis and diabetes mellitus. iScience. 2024 Feb 5;27(3):109135. doi: 10.1016/j.isci.2024.109135. PMID: 38380250; PMCID: PMC10877940.
• Ridolfi F, Amorim G, Peetluk LS, Haas DW, Staats C, Araújo-Pereira M, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Andrade BB, Rolla VC, Sterling TR; Regional Prospective Observational Research in Tuberculosis (RePORT)–Brazil Consortium. Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil. J Infect Dis. 2024 Mar 14;229(3):813-823. doi: 10.1093/infdis/jiae025. PMID: 38262629; PMCID: PMC10938211.
• Araújo-Pereira M, Arriaga MB, Carvalho ACC, Spener-Gomes R, Schmaltz CAS, Nogueira BMF, Figueiredo MC, Turner MM, Cordeiro-Santos M, Rolla VC, Sterling TR, Andrade BB, Kritski AL; Regional Prospective Observational Research for Tuberculosis (RePORT)-Brazil Consortium. Isoniazid Monoresistance and Antituberculosis Treatment Outcome in Persons With Pulmonary Tuberculosis in Brazil. Open Forum Infect Dis. 2024 Jan 8;11(1):ofad691. doi: 10.1093/ofid/ofad691. PMID: 38221983; PMCID: PMC10785213.
• Enane LA, Duda SN, Chanyachukul T, Bolton-Moore C, Navuluri N, Messou E, Mbonze N, McDade LR, Figueiredo MC, Ross J, Evans D, Diero L, Akpata R, Zotova N, Freeman A, Pierre MF, Rupasinghe D, Ballif M, Byakwaga H, de Castro N, Tabala M, Sterling TR, Sohn AH, Fenner L, Wools-Kaloustian K, Poda A, Yotebieng M, Huebner R, Marcy O; International epidemiology Databases to Evaluate AIDS. The Tuberculosis Sentinel Research Network (TB-SRN) of the International epidemiology Databases to Evaluate AIDS (IeDEA): protocol for a prospective cohort study in Africa, Southeast Asia and Latin America. BMJ Open. 2024 Jan 9;14(1):e079138. doi: 10.1136/bmjopen-2023-079138. PMID: 38195167; PMCID: PMC10806577.
• Garcia LS, Costa AG, Araújo-Pereira M, Spener-Gomes R, Aguiar AF, Souza AB, Lima LOA, Benjamin A, Rocha MS, Moreira ASR, Silva J, Santos SRN, Lourenço MC, Figueiredo MC, Turner MM, Kritski AL, Rolla VC, Sterling TR, Andrade BB, Cordeiro-Santos M; RePORT Brazil Consortium. The Xpert® MTB/RIF cycle threshold value predicts M. tuberculosis transmission to close contacts in a Brazilian prospective multicenter cohort. Clin Infect Dis. 2024 Jan 3:ciad794. doi: 10.1093/cid/ciad794. Epub ahead of print. PMID: 38170196.
• Amaral EP, Namasivayam S, Queiroz ATL, Fukutani E, Hilligan KL, Aberman K, Fisher L, Bomfim CCB, Kauffman K, Buchanan J, Santuo L, Gazzinelli-Guimaraes PH, Costa DL, Teixeira MA, Barreto-Duarte B, Rocha CG, Santana MF, Cordeiro-Santos M, Barber DL, Wilkinson RJ, Kramnik I, Igarashi K, Scriba T, Mayer-Barber KD, Andrade BB, Sher A. BACH1 promotes tissue necrosis and Mycobacterium tuberculosis susceptibility. Nat Microbiol. 2024 Jan;9(1):120-135. doi: 10.1038/s41564-023-01523-7. Epub 2023 Dec 8. PMID: 38066332; PMCID: PMC10769877.
• Rocha EF, Vinhaes CL, Araújo-Pereira M, Mota TF, Gupte AN, Kumar NP, Arriaga MB, Sterling TR, Babu S, Gaikwad S, Karyakarte R, Mave V, Kulkarni V, Paradkar M, Viswanathan V, Kornfeld H, Gupta A, Andrade BB, Queiroz ATL; RePORT Brazil; RePORT India Consortia. The sound of silent RNA in tuberculosis and the lncRNA role on infection. iScience. 2023 Dec 8;27(1):108662. doi: 10.1016/j.isci.2023.108662. PMID: 38205253; PMCID: PMC10777062.

2023

• Arriaga MB, Araújo-Pereira M, Andrade VMB, Queiroz ATL, Fernandes CD, Sales C, Aliaga JG, Shivakoti R, Lecca L, Calderon RI, Andrade BB. Influence of dietary pattern on anti-tuberculosis treatment outcomes in persons with dysglycemia: a Peruvian prospective cohort study. Front Nutr. 2023 Dec 18;10:1254983. doi: 10.3389/fnut.2023.1254983. PMID: 38164414; PMCID: PMC10757910.
• Amaral EP, Namasivayam S, Queiroz ATL, Fukutani E, Hilligan KL, Aberman K, Fisher L, Bomfim CCB, Kauffman K, Buchanan J, Santuo L, Gazzinelli-Guimaraes PH, Costa DL, Teixeira MA, Barreto-Duarte B, Rocha CG, Santana MF, Cordeiro-Santos M, Barber DL, Wilkinson RJ, Kramnik I, Igarashi K, Scriba T, Mayer-Barber KD, Andrade BB, Sher A. BACH1 promotes tissue necrosis and Mycobacterium tuberculosis susceptibility.Nat Microbiol. 2023 Dec 8. doi: 10.1038/s41564-023-01523-7. PMID: 38066332.
• Araújo-Pereira M, Andrade BB. Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients. Int J Tuberc Lung Dis. 2023 Dec 1;27(12):880-881. doi: 10.5588/ijtld.23.0503. PMID: 38042973.
• du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ. Standards for clinical trials for treating TB. Int J Tuberc Lung Dis. 2023 Dec 1;27(12):885-898. doi: 10.5588/ijtld.23.0341. PMID: 38042969; PMCID: PMC10719894.
• Kengo A, Nabisere R, Gausi K, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Denti P, Sekaggya-Wiltshire C. Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043023. doi: 10.1128/aac.00430-23. PMID: 37850738; PMCID: PMC10648962.
• Hill PC, Cobelens F, Martinez L, Behr MA, Churchyard G, Evans T, Fiore-Gartland AJ, Garcia-Basteiro AL, Hanekom W, Rangaka MX, Vekemans J, White RG. An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine Trials. J Infect Dis. 2023 Nov 2;228(9):1150-1153. doi: 10.1093/infdis/jiad356. PMID: 37607272.
• Kengo A, Gausi K, Nabisere R, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Sekaggya-Wiltshire C, Denti P. Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043123. doi: 10.1128/aac.00431-23. PMID: 37850737; PMCID: PMC10649026.
• Geiger K, Patil A, Budhathoki C, Dooley KE, Lowensen K, Ndjeka N, Ngozo J, Farley JE. Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity. J Acquir Immune Defic Syndr. 2023 Nov 1;94(3):253-261. doi: 10.1097/QAI.0000000000003268. PMID: 37757847; PMCID: PMC10592374.
• Hill PC, Cobelens F, Martinez L, Garcia-Basteiro A, Behr M, Rangaka MX, Churchyard G, Evans T, Hanekom W, White R. Correspondence Regarding: McShane H. Improving TB vaccine trial efficiency: A tough nut to crack. J Infect Dis. 2023 Oct 28:jiad466. doi: 10.1093/infdis/jiad466. PMID: 37897697.
• Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Herna Sari A, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. Lancet. 2023 Oct 21;402(10411):1473-1498. doi: 10.1016/S0140-6736(23)01379-X. PMID: 37716363.
• Wasmann RE, Masini T, Viney K, Verkuijl S, Brands A, Hesseling AC, McIlleron H, Denti P, Dooley KE. A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis. Front Pharmacol. 2023 Apr 25;14:1055329. doi: 10.3389/fphar.2023.1055329. PMID: 37180707; PMCID: PMC10167634.
• Nelson KN, Churchyard G, Cobelens F, Hanekom WA, Hill PC, Lopman B, Mave V, Rangaka MX, Vekemans J, White RG, Wong EB, Martinez L, García-Basteiro AL. Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?Lancet Microbe. 2023 Aug;4(8):e651-e656. doi: 10.1016/S2666-5247(23)00112-X. PMID: 37329893; PMCID: PMC10393779.
• Krishnan S, Wu X, Kim S, McIntire K, Naini L, Hughes MD, Dawson R, Mave V, Gaikwad S, Sanchez J, Mendoza-Ticona A, Gonzales P, Comins K, Shenje J, Fontain SN, Omozoarhe A, Mohapi L, Lalloo UG, Garcia Ferreira AC, Mugah C, Harrington M, Shah NS, Hesseling AC, Churchyard G, Swindells S, Gupta A. 1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2023 Sep 18;77(6):892-900. doi: 10.1093/cid/ciad301. PMID: 37227925; PMCID: PMC10681643.
• Verboven L, Callens S, Black J, Maartens G, Dooley KE, Potgieter S, Cartuyvels R; SMARTT team; Laukens K, Warren RM, Van Rie A. A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis. Res Sq [Preprint]. 2023 Feb 16:rs.3.rs-2525765. doi: 10.21203/rs.3.rs-2525765/v1. PMID: 36824956; PMCID: PMC9949242.
• Dooley KE, Hendricks B, Gupte N, Barnes G, Narunsky K, Whitelaw C, Smit T, Ignatius EH, Friedman A, Dorman SE, Dawson R. Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results. Am J Respir Crit Care Med. 2023 Apr 1;207(7):929-935. doi: 10.1164/rccm.202208-1475OC. PMID: 36455068.
• Naidoo A, Dooley KE. Dolutegravir once daily with rifampicin for HIV and tuberculosis. Lancet HIV. 2023 Jul;10(7):e422-e423. doi: 10.1016/S2352-3018(23)00115-7. PMID: 37230100; PMCID: PMC10594392.
• Kawuma AN, Wasmann RE, Dooley KE, Maartens G, Denti P. Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model. Br J Clin Pharmacol. 2023 Mar;89(3):1216-1221. doi: 10.1111/bcp.15604. PMID: 36385424.
• Deshmukh S, Sane M, Gaikwad S, Sahasrabudhe T, Barthwal M, Lokhande R, Raskar S, Kagal A, Dharmshale S, Pradhan N, Gupte A, Alfarisi O, Gupta A, Dooley KE, Gupte N, Golub JE, Mave V. Sex Differences in TB Clinical Presentation, Drug Exposure, and Treatment Outcomes in India. Chest. 2023 Apr;163(4):778-789. doi: 10.1016/j.chest.2022.09.024. PMID: 36174745; PMCID: PMC10258435.
• Martinson NA, Nonyane BAS, Genade LP, Berhanu RH, Naidoo P, Brey Z, Kinghorn A, Nyathi S, Young K, Hausler H, Connell L, Lutchminarain K, Swe Swe-Han K, Vreede H, Said M, von Knorring N, Moulton LH, Lebina L. Evaluating systematic targeted universal testing for tuberculosis in primary care clinics of South Africa: A cluster-randomized trial (The TUTT Trial). PLoS Med. 2023 May 22;20(5):e1004237. doi: 10.1371/journal.pmed.1004237. PMID: 37216385; PMCID: PMC10263318.
• Audet CM, Seabi T, Ngobeni S, Berhanu RH, Wagner RG. Pulmonary tuberculosis vs. Tindzhaka and Mafularha: A mixed methods inquiry of traditional healers' perceptions of tuberculosis in rural South Africa. PLOS Glob Public Health. 2023 Apr 21;3(4):e0001611. doi: 10.1371/journal.pgph.0001611. PMID: 37083848; PMCID: PMC10121049.
• Berhanu RH, Lebina L, Nonyane BAS, Milovanovic M, Kinghorn A, Connell L, Nyathi S, Young K, Hausler H, Naidoo P, Brey Z, Shearer K, Genade L, Martinson NA. Yield of Facility-based Targeted Universal Testing for Tuberculosis With Xpert and Mycobacterial Culture in High-Risk Groups Attending Primary Care Facilities in South Africa. Clin Infect Dis. 2023 May 3;76(9):1594-1603. doi: 10.1093/cid/ciac965. PMID: 36610730; PMCID: PMC10156124.
• Gupta A, Singh P, Aaron L, Montepiedra G, Chipato T, Stranix-Chibanda L, Chanaiwa V, Vhembo T, Mutambanengwe M, Masheto G, Raesi M, Bradford S, Golner A, Costello D, Kulkarni V, Shayo A, Kabugho E, Jean-Phillippe P, Chakhtoura N, Sterling TR, Theron G, Weinberg A. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. Lancet Child Adolesc Health. 2023 Aug 24. doi: 10.1016/S2352-4642(23)00174-8. PMID: 37634517.
• Sack DE, Brantley M, Ratliff M, Mathieson S, Turner M, Pettit AC, Sterling TR, Rebeiro PF. Misclassification of Loss to Care Among Persons with HIV: Improved Capture of Silent Transfers through Surveillance Linkage using Statewide Mandatorily Reported Laboratory Measures. Clin Infect Dis. 2023 Aug 9. doi: 10.1093/cid/ciad461. PMID: 37555632.
• Ryckman T, Weiser J, Gombe M, Turner K, Soni P, Tarlton D, Mazhidova N, Churchyard G, Chaisson RE, Dowdy DW. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis. Lancet Glob Health. 2023 Aug;11(8):e1205-e1216. doi: 10.1016/S2214-109X(23)00251-6. PMID: 37474228; PMCID: PMC10369017.
• Agyemang N, Scarsi KK, Baker P, Smeaton LM, Podany AT, Olefsky M, Woolley E, Barr E, Pham M, Mawlana S, Supparatpinyo K, Gatechompol S, Jalil EM, Gadama L, Badal-Faesen S, Van Schalkwyk M, Kayama C, Belaunzaran-Zamudio PF, Godfrey C, Cohn SE, Mngqibisa R, Haas DW. Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis. Pharmacogenet Genomics. 2023 Aug 1;33(6):126-135. doi: 10.1097/FPC.0000000000000501. PMID: 37306344; PMCID: PMC10309098.
• Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States. Ann Am Thorac Soc. 2023 Sep;20(9):1258-1266. doi: 10.1513/AnnalsATS.202212-1005OC. PMID: 37159954.
• Schwalb A, Bergstrom M, Woodd S, Rehman AM, PrayGod G, Kasonka L, Koethe JR, Filteau S, Houben RMGJ. Impact of micro- and macronutrient status on the incidence of tuberculosis: An examination of an African cohort initiating antiretroviral therapy. PLOS Glob Public Health. 2023 Jul 13;3(7):e0002007. doi: 10.1371/journal.pgph.0002007. PMID: 37440476; PMCID: PMC10343057.
• Malhotra A, Nonyane BAS, Shirey E, Mulder C, Hippner P, Mulatu F, Ratshinanga A, Mitiku P, Cohn S, Conradie G, Chihota V, Chaisson RE, Churchyard GJ, Golub J, Dowdy D, Sohn H, Charalambous S, Bedru A, Salazar-Austin N. Pragmatic cluster-randomized trial of home-based preventive treatment for TB in Ethiopia and South Africa (CHIP-TB). Trials. 2023 Jul 25;24(1):475. doi: 10.1186/s13063-023-07514-7. PMID: 37491264; PMCID: PMC10367260.
• Davies LRL, Smith MT, Cizmeci D, Fischinger S, Shih-Lu Lee J, Lu LL, Layton ED, Grant AD, Fielding K, Stein CM, Boom WH, Hawn TR, Fortune SM, Wallis RS, Churchyard GJ, Alter G, Seshadri C. IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners. EBioMedicine. 2023 Jul;93:104678. doi: 10.1016/j.ebiom.2023.104678. PMID: 37379655; PMCID: PMC10320233.
• Araújo-Pereira M, Krishnan S, Salgame P, Manabe YC, Hosseinipour MC, Bisson G, Severe DP, Rouzier V, Leong S, Mave V, Sawe FK, Siika AM, Kanyama C, Dadabhai SS, Lama JR, Valencia-Huamani J, Badal-Faesen S, Lalloo UG, Naidoo K, Mohapi L, Kityo C, Andrade BB, Gupta A. Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV. EClinicalMedicine. 2023 Jun 2;60:102030. doi: 10.1016/j.eclinm.2023.102030. PMID: 37287871; PMCID: PMC10242630.
• Maenetje P, Baik Y, Schramm DB, Vangu MDW, Wallis RS, Mlotshwa M, Tiemessen CT, Li Y, Kornfeld H, Churchyard G, Auld SC, Bisson GP. Circulating biomarkers, FeNO, and lung function in patients with HIV and tuberculosis. J Infect Dis. 2023 Jun 30. doi: 10.1093/infdis/jiad232. PMID: 37386883.
• Krause R, Warren CM, Simmons JD, Rebeiro PF, Maruri F, Karim F, Sterling TR, Koethe JR, Leslie A, van der Heijden YF. Failure to decrease HbA1c levels following TB treatment is associated with elevated Th1/Th17 CD4+ responses. Front Immunol. 2023 May 29;14:1151528. doi: 10.3389/fimmu.2023.1151528. PMID: 37313404; PMCID: PMC10258338.
• Queiroz ATL, Vinhaes CL, Fukutani ER, Gupte AN, Kumar NP, Fukutani KF, Arriaga MB, Sterling TR, Babu S, Gaikwad S, Karyakarte R, Mave V, Viswanathan V, Gupta A, Andrade BB, Kornfeld H. A multi-center, prospective cohort study of whole blood gene expression in the tuberculosis-diabetes interaction. Sci Rep. 2023 May 12;13(1):7769. doi: 10.1038/s41598-023-34847-9. PMID: 37173394; PMCID: PMC10180618.
• Araújo-Pereira M, Nogueira BMF, Spener-Gomes R, Carvalho ACC, Sant'Anna FM, Figueiredo MC, Turner MM, Kritski AL, Cordeiro-Santos M, Rolla VC, Sterling TR, Andrade BB. Anemia and anti-tuberculosis treatment outcome in persons with pulmonary tuberculosis. J Infect Public Health. 2023 Jun;16(6):974-980. doi: 10.1016/j.jiph.2023.04.009. PMID: 37121049; PMCID: PMC10194045.
• Araújo-Pereira M, Schutz C, Barreto-Duarte B, Barr D, Villalva-Serra K, Vinhaes CL, Ward A, Meintjes G, Andrade BB. Interplay between systemic inflammation, anemia, and mycobacterial dissemination and its impact on mortality in TB-associated HIV. Front Immunol. 2023 Apr 18;14:1177432. doi: 10.3389/fimmu.2023.1177432. PMID: 37143662; PMCID: PMC10151654.
• van der Heijden YF, Maruri F, Blackman A, Morrison R, Guo Y, Sterling TR. Mycobacterium tuberculosis Gene Expression Associated With Fluoroquinolone Resistance and Efflux Pump Inhibition. J Infect Dis. 2023 Aug 16;228(4):469-478. doi: 10.1093/infdis/jiad112. PMID: 37079382; PMCID: PMC10428193.
• Rangaka MX, Frick M, Churchyard G, García-Basteiro AL, Hatherill M, Hanekom W, Hill PC, Hamada Y, Quaife M, Vekemans J, White RG, Cobelens F. Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment. Lancet Respir Med. 2023 Apr;11(4):380-390. doi: 10.1016/S2213-2600(23)00084-X. PMID: 36966794.
• Kim S, Hesseling AC, Wu X, Hughes MD, Shah NS, Gaikwad S, Kumarasamy N, Mitchell E, Leon M, Gonzales P, Badal-Faesen S, Lourens M, Nerette S, Shenje J, de Koker P, Nedsuwan S, Mohapi L, Chakalisa UA, Mngqbisa R, Escada RODS, Ouma S, Heckman B, Naini L, Gupta A, Swindells S, Churchyard G. Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household. PLoS One. 2023 Mar 17;18(3):e0283290. doi: 10.1371/journal.pone.0283290. PMID: 36930628; PMCID: PMC10022776.
• Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine. Lancet Respir Med. 2023 Sep;11(9):782-790. doi: 10.1016/S2213-2600(23)00096-6. PMID: 36966788.
• Baik Y, Maenetje P, Schramm D, Tiemessen C, Ncube I, Churchyard G, Wallis R, Vangu MD, Kornfeld H, Li Y, Auld SC, Bisson GP. Lung function and collagen 1a levels are associated with changes in 6 min walk test distance during treatment of TB among HIV-infected adults. BMC Pulm Med. 2023 Feb 3;23(1):53. doi: 10.1186/s12890-023-02325-7. PMID: 36737697; PMCID: PMC9896708.
• Jarrett RT, van der Heijden Y, Shotwell MS, Chihota V, Marzinke MA, Chaisson RE, Dooley KE, Churchyard GJ. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0129722. doi: 10.1128/aac.01297-22. PMID: 36622148; PMCID: PMC9933705.
• Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 Feb 8;76(3):e580-e589. doi: 10.1093/cid/ciac707. PMID: 36041016; PMCID: PMC10169427.
• Sant Anna FM, Araújo-Pereira M, Schmaltz CAS, Arriaga MB, Andrade BB, Rolla VC. Impact of adverse drug reactions on the outcomes of tuberculosis treatment. PLoS One. 2023 Feb 7;18(2):e0269765. doi: 10.1371/journal.pone.0269765. PMID: 36749743; PMCID: PMC9904486.
• Pietersen E, Anderson K, Cox H, Dheda K, Bian A, Shepherd BE, Sterling TR, Warren RM, van der Heijden YF. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa. PLoS One. 2023 Feb 13;18(2):e0281097. doi: 10.1371/journal.pone.0281097. PMID: 36780443; PMCID: PMC9925007.
• Peters JS, McIvor A, Papadopoulos AO, Masangana T, Gordhan BG, Waja Z, Otwombe K, Letutu M, Kamariza M, Sterling TR, Bertozzi CR, Martinson NA, Kana BD. Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response. Front Cell Infect Microbiol. 2023 Jan 12;12:1064148. doi: 10.3389/fcimb.2022.1064148. PMID: 36710965; PMCID: PMC9877613.
• Otero L, Zetola N, Campos M, Zunt J, Bayer A, Curisinche M, Ochoa T, Reyes M, Vega V, Van der Stuyft P, Sterling TR. Isoniazid preventive therapy completion in children under 5 years old who are contacts of tuberculosis cases in Lima, Peru. Trials. 2023 Jan 24;24(1):54. doi: 10.1186/s13063-022-07062-6. PMID: 36694242; PMCID: PMC9871424

2022

• Holzman SB, Perry A, Saleeb P, Pyan A, Keh C, Salcedo K, Narita M, Ahmed A, Miller TL, Pettit AC, Khurana R, Whipple M, Katz D, Largen A, Krueger A, Shah M; Tuberculosis Epidemiologic Studies Consortium. Evaluation of the Latent Tuberculosis Care Cascade Among Public Health Clinics in the United States. Clin Infect Dis. 2022 Nov 14;75(10):1792-1799. doi: 10.1093/cid/ciac248. PMID: 35363249.
• Naidoo A, Dooley KE, Naidoo K, Padayatchi N, Yende-Zuma N, Perumal R, Dorse G, Boodhram R, Osuala EC. INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen. BMJ Open. 2022 Nov 10;12(11):e067765. doi: 10.1136/bmjopen-2022-067765. PMID: 36356989; PMCID: PMC9660663.
• Jones AJ, Mathad JS, Dooley KE, Eke AC. Evidence for Implementation: Management of TB in HIV and Pregnancy. Curr HIV/AIDS Rep. 2022 Dec;19(6):455-470. doi: 10.1007/s11904-022-00641-x. PMID: 36308580; PMCID: PMC9617238.
• Bezerra AL, Moreira ADSR, Isidoro-Gonçalves L, Lara CFDS, Amorim G, Silva EC, Kritski AL, Carvalho ACC. Clinical, laboratory, and radiographic aspects of patients with pulmonary tuberculosis and dysglycemia and tuberculosis treatment outcomes. J Bras Pneumol. 2022 Nov 28;48(6):e20210505. doi: 10.36416/1806-3756/e20210505. PMID: 36449815; PMCID: PMC9747138.
• Sobral L, Arriaga MB, Souza AB, Araújo-Pereira M, Barreto-Duarte B, Sales C, Rocha MS, Benjamin A, Moreira ASR, de Oliveira JG, Carvalho AC, Spener-Gomes R, Figueiredo MC, Cavalcante S, Durovni B, Lapa-E-Silva JR, Kritski AL, Rolla VC, Sterling TR, Cordeiro-Santos M, Andrade BB. Determinants of losses in the tuberculosis infection cascade of care among children and adolescent contacts of pulmonary tuberculosis cases: A Brazilian multi-centre longitudinal study. Lancet Reg Health Am. 2022 Nov;15:100358. doi: 10.1016/j.lana.2022.100358. PMID: 36438860; PMCID: PMC9696515.
• Nogueira BMF, Krishnan S, Barreto-Duarte B, Araújo-Pereira M, Queiroz ATL, Ellner JJ, Salgame P, Scriba TJ, Sterling TR, Gupta A, Andrade BB. Diagnostic biomarkers for active tuberculosis: progress and challenges. EMBO Mol Med. 2022 Oct 31:e14088. doi: 10.15252/emmm.202114088. PMID: 36314872.
• Villalva-Serra K, Barreto-Duarte B, Nunes VM, Menezes RC, Rodrigues MMS, Queiroz ATL, Arriaga MB, Cordeiro-Santos M, Kritski AL, Sterling TR, Araújo-Pereira M, Andrade BB. Tuberculosis treatment outcomes of diabetic and non-diabetic TB/HIV co-infected patients: A nationwide observational study in Brazil. Front Med (Lausanne). 2022 Sep 16;9:972145. doi: 10.3389/fmed.2022.972145. PMID: 36186793; PMCID: PMC9523014.
• Miner MD, Hatherill M, Mave V, Gray GE, Nachman S, Read SW, White RG, Hesseling A, Cobelens F, Patel S, Frick M, Bailey T, Seder R, Flynn J, Rengarajan J, Kaushal D, Hanekom W, Schmidt AC, Scriba TJ, Nemes E, Andersen-Nissen E, Landay A, Dorman SE, Aldrovandi G, Cranmer LM, Day CL, Garcia-Basteiro AL, Fiore-Gartland A, Mogg R, Kublin JG, Gupta A, Churchyard G. Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel. Lancet HIV. 2022 Nov;9(11):e791-e800. doi: 10.1016/S2352-3018(22)00255-7. PMID: 36240834; PMCID: PMC9667733.
• Van Rie A, De Vos E, Costa E, Verboven L, Ndebele F, Heupink TH, Abrams S; SMARTT team; Fanampe B, Van der Spoel Van Dyk A, Charalambous S, Churchyard G, Warren R. Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial. Trials. 2022 Oct 8;23(1):864. doi: 10.1186/s13063-022-06793-w. PMID: 36209235; PMCID: PMC9548157.
• Cubillos-Angulo JM, Nogueira BMF, Arriaga MB, Barreto-Duarte B, Araújo-Pereira M, Fernandes CD, Vinhaes CL, Villalva-Serra K, Nunes VM, Miguez-Pinto JP, Amaral EP, Andrade BB. Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs. Front Med (Lausanne). 2022 Sep 23;9:970408. doi: 10.3389/fmed.2022.970408. PMID: 36213651; PMCID: PMC9537567.
• Guo Y, van der Heijden YF, Maruri F, Jiang L, Morrison R, Sterling TR. RNA editing in Mycobacterium tuberculosis. Microbiol Res. 2022 Nov;264:127174. doi: 10.1016/j.micres.2022.127174. PMID: 36067705.
• Ntshiqa T, Chihota V, Mansukhani R, Nhlangulela L, Velen K, Charalambous S, Maenetje P, Hawn TR, Wallis R, Grant AD, Fielding K, Churchyard G. Comparing QuantiFERON-TB Gold Plus with QuantiFERON-TB Gold in-tube for diagnosis of latent tuberculosis infection among highly TB exposed gold miners in South Africa. Gates Open Res. 2022 Aug 18;5:66. doi: 10.12688/gatesopenres.13191.3. PMID: 37560544; PMCID: PMC10407057.
• Schwalb A, Cachay R, Wright A, Phillips PPJ, Kaur P, Diacon AH, Ugarte-Gil C, Mitnick CD, Sterling TR, Gotuzzo E, Horsburgh CR. Factors associated with screening failure and study withdrawal in multidrug-resistant TB. Int J Tuberc Lung Dis. 2022 Sep 1;26(9):820-825. doi: 10.5588/ijtld.21.0729. PMID: 35996282.
• Lang R, Humes E, Hogan B, Lee J, D'Agostino R, Massaro J, Kim A, Meigs JB, Borowsky L, He W, Lyass A, Cheng D, Kim HN, Klein MB, Cachay ER, Bosch RJ, Gill MJ, Silverberg MJ, Thorne JE, McGinnis K, Horberg MA, Sterling TR, Triant VA, Althoff KN. Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection. J Am Heart Assoc. 2022 Sep 21:e026473. doi: 10.1161/JAHA.122.026473. PMID: 36129038.
• Schwalb A, Cachay R, Wright A, Phillips PPJ, Kaur P, Diacon AH, Ugarte-Gil C, Mitnick CD, Sterling TR, Gotuzzo E, Horsburgh CR. Factors associated with screening failure and study withdrawal in multidrug-resistant TB. Int J Tuberc Lung Dis. 2022 Sep 1;26(9):820-825. doi: 10.5588/ijtld.21.0729. PMID: 35996282.
• Pettit AC, Phillips PP, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S; Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349). Clin Infect Dis. 2022 Aug 30:ciac707. doi: 10.1093/cid/ciac707. PMID: 36041016.
• Magohe A, Kimario J, Lukmanji Z, Hendricks K, Koethe JR, Neke NM, Tvaroha S, Connor R, Mackenzie T, Waddell R, Maro I, Matee M, Pallangyo K, Bakari M, Horsburgh CR, von Reyn CF. Randomized, controlled trial of a protein-calorie supplement for women coinfected with HIV-TB. Int J Tuberc Lung Dis. 2022 Aug 1;26(8):798-800. doi: 10.5588/ijtld.21.0669. PMID: 35898141.
• Anderson K, Pietersen E, Dheda K, van der Heijden YF. Comparison of treatment outcome definitions in drug-resistant tuberculosis patients with high incidence of acquired second-line drug resistance. Afr J Thorac Crit Care Med. 2022 Jul 15;28(2):10.7196/AJTCCM.2022.v28i2.177. doi: 10.7196/AJTCCM.2022.v28i2.177. PMID: 35991341; PMCID: PMC9379990.
• Arriaga MB, Karim F, Queiroz ATL, Araújo-Pereira M, Barreto-Duarte B, Sales C, Moosa MS, Mazibuko M, Milne GL, Maruri F, Serezani CH, Koethe JR, Figueiredo MC, Kritski AL, Cordeiro-Santos M, Rolla VC, Sterling TR, Leslie A, Andrade BB. Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis. Front Immunol. 2022 Jul 8;13:919802. doi: 10.3389/fimmu.2022.919802. PMID: 35874781; PMCID: PMC9304990.
• Simmons JD, Dill-McFarland KA, Stein CM, Van PT, Chihota V, Ntshiqa T, Maenetje P, Peterson GJ, Benchek P, Nsereko M, Velen K, Fielding KL, Grant AD, Gottardo R, Mayanja-Kizza H, Wallis RS, Churchyard G, Boom WH, Hawn TR. Monocyte Transcriptional Responses to Mycobacterium tuberculosis Associate with Resistance to Tuberculin Skin Test and Interferon Gamma Release Assay Conversion. mSphere. 2022 Jun 29;7(3):e0015922. doi: 10.1128/msphere.00159-22. PMID: 35695527; PMCID: PMC9241521.
• Garcia-Basteiro AL, White RG, Tait D, Schmidt AC, Rangaka MX, Quaife M, Nemes E, Mogg R, Hill PC, Harris RC, Hanekom WA, Frick M, Fiore-Gartland A, Evans T, Dagnew AF, Churchyard G, Cobelens F, Behr MA, Hatherill M. End-point definition and trial design to advance tuberculosis vaccine development. Eur Respir Rev. 2022 Jun 7;31(164):220044. doi: 10.1183/16000617.0044-2022. PMID: 35675923; PMCID: PMC9488660.
• Wada PY, Costa AG, Araújo-Pereira M, Barreto-Duarte B, Souza AB, Rocha MS, Figueiredo MC, Turner MM, Rolla VC, Kritski AL, Cordeiro-Santos M, Andrade BB, Sterling TR, Rebeiro PF; Regional Prospective Observational Research in Tuberculosis (RePORT) Brazil Consortium. Possible Sex Difference in Latent Tuberculosis Infection Risk among Close Tuberculosis Contacts. Int J Infect Dis. 2022 Jul 14:S1201-9712(22)00426-X. doi: 10.1016/j.ijid.2022.07.031. PMID: 35843494.
• Ridolfi F, Peetluk L, Amorim G, Turner M, Figueiredo M, Cordeiro-Santos M, Cavalcante S, Kritski A, Durovni B, Andrade B, Sterling TR, Rolla V; Regional Prospective Observational Research in Tuberculosis (RePORT)–Brazil Consortium. TB treatment outcomes in Brazil: different predictors for each type of unsuccessful outcome. Clin Infect Dis. 2022 Jul 5:ciac541. doi: 10.1093/cid/ciac541. PMID: 35788646.
• Nguenha D, Acacio S, Murias-Closas A, Ramanlal N, Saavedra B, Karajeanes E, Mudumane B, Mambuque E, Gomes N, Losada I, Oliveras L, Naueia E, Sterling TR, Amorim G, Moon TD, Menéndez C, Vaz P, López-Varela E, Garcia-Basteiro AL. Prevalence and clinical characteristics of pulmonary TB among pregnant and post-partum women. Int J Tuberc Lung Dis. 2022 Jul 1;26(7):641-649. doi: 10.5588/ijtld.21.0567. PMID: 35768920.
• Araújo-Pereira M, Barreto-Duarte B, Arriaga MB, Musselwhite LW, Vinhaes CL, Belaunzaran-Zamudio PF, Rupert A, Montaner LJ, Lederman MM, Sereti I, Madero JGS, Andrade BB. Relationship Between Anemia and Systemic Inflammation in People Living With HIV and Tuberculosis: A Sub-Analysis of the CADIRIS Clinical Trial. Front Immunol. 2022 Jun 23;13:916216. doi: 10.3389/fimmu.2022.916216. PMID: 35812431; PMCID: PMC9260499.
• Queiroz ATL, Araújo-Pereira M, Barreto-Duarte B, Gomes-Silva A, Costa AG, Andrade AMS, Miguez-Pinto JP, Spener-Gomes R, Souza AB, Benjamin A, Sant'Anna F, Figueiredo MC, Mave V, Salgame P, Ellner JJ, Sterling TR, Cordeiro-Dos-Santos M, Andrade BB, Rolla VC. Immunologic Biomarkers in Peripheral Blood of Persons With Tuberculosis and Advanced HIV. Front Immunol. 2022 Jun 10;13:890003. doi: 10.3389/fimmu.2022.890003. PMID: 35757685; PMCID: PMC9226490.
• Porter M, Choshi P, Pedretti S, Chimbetete T, Smith R, Meintjes G, Phillips E, Lehloenya R, Peter J. IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-line Anti-tuberculosis Drugs in an HIV Endemic Setting. J Invest Dermatol. 2022 Jun 1:S0022-202X(22)01500-7. doi: 10.1016/j.jid.2022.05.1059. PMID: 35659939.
• Anderson K, Pietersen E, Shepherd BE, Bian A, Dheda K, Warren R, Sterling TR, van der Heijden YF. High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence. HIV Med. 2022 May 24. doi: 10.1111/hiv.13318. PMID: 35608016.
• Walker NF, Karim F, Moosa M, Moodley S, Mazibuko M, Khan K, Sterling TR, van der Heijden YF, Grant AD, Elkington PT, Pym A, Leslie A. Elevated Plasma Matrix Metalloproteinase-8 associates with Sputum Culture Positivity in Pulmonary Tuberculosis. J Infect Dis. 2022 May 1:jiac160. doi: 10.1093/infdis/jiac160. PMID: 35510939.
• Vesga JF, Lienhardt C, Nsengiyumva P, Campbell JR, Oxlade O, den Boon S, Falzon D, Schwartzman K, Churchyard G, Arinaminpathy N. Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis. BMC Med. 2022 May 18;20(1):182. doi: 10.1186/s12916-022-02378-1. PMID: 35581650; PMCID: PMC9115962.
• Bender Ignacio RA, Long J, Saha A, Nguyen FK, Joudeh L, Valinetz E, Mendelsohn SC, Scriba TJ, Hatherill M, Janes H, Churchyard G, Buchbinder S, Duerr A, Shah JA, Hawn TR. Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition. PLoS One. 2022 May 3;17(5):e0267729. doi: 10.1371/journal.pone.0267729. PMID: 35503767; PMCID: PMC9064099.
• Antimycobacterial Susceptibility Testing Group. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. Eur Respir J. 2022 Apr 14;59(4):2200166. doi: 10.1183/13993003.00166-2022. PMID: 35422426; PMCID: PMC9059840.
• Holzman SB, Perry A, Saleeb P, Pyan A, Keh C, Salcedo K, Narita M, Ahmed A, Miller TL, Pettit AC, Khurana R, Whipple M, Katz D, Largen A, Krueger A, Shah M. Evaluation of the latent tuberculosis care cascade among public health clinics in the United States. Clin Infect Dis. 2022 Apr 1:ciac248. doi: 10.1093/cid/ciac248. PMID: 35363249.
• Crabtree-Ramirez B, Jenkins CA, Shepherd BE, Jayathilake K, Veloso VG, Carriquiry G, Gotuzzo E, Cortes CP, Padgett D, McGowan C, Sierra-Madero J, Koenig S, Pape JW, Sterling TR; CCASAnet Region of IeDEA. Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy. BMC Infect Dis. 2022 Apr 5;22(1):341. doi: 10.1186/s12879-022-07330-5. PMID: 35382770; PMCID: PMC8985331.
• Mulenga H, Fiore-Gartland A, Mendelsohn SC, Penn-Nicholson A, Mbandi SK, Nemes E, Borate B, Musvosvi M, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS Study Team. Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. EClinicalMedicine. 2022 Apr 21;47:101396. doi: 10.1016/j.eclinm.2022.101396. PMID: 35497063; PMCID: PMC9046130.
• Mendelsohn SC, Mbandi SK, Fiore-Gartland A, Penn-Nicholson A, Musvosvi M, Mulenga H, Fisher M, Hadley K, Erasmus M, Nombida O, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M, Scriba TJ. Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. Commun Med (Lond). 2022;2(1):26. doi: 10.1038/s43856-022-00086-8. PMID: 35342900; PMCID: PMC8954216.
• Chihota VN, Ntshiqa T, Maenetje P, Mansukhani R, Velen K, Hawn TR, Wallis R, Grant AD, Churchyard GJ, Fielding K. Resistance to Mycobacterium tuberculosis infection among highly TB exposed South African gold miners. PLoS One. 2022 Mar 18;17(3):e0265036. doi: 10.1371/journal.pone.0265036. PMID: 35302992; PMCID: PMC8932619.
• Mendelsohn SC, Fiore-Gartland A, Awany D, Mulenga H, Mbandi SK, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS-HR Study Team. Clinical predictors of pulmonary tuberculosis among South African adults with HIV. EClinicalMedicine. 2022 Mar 5;45:101328. doi: 10.1016/j.eclinm.2022.101328. PMID: 35274090; PMCID: PMC8902614.
• Kim S, Wu X, Hughes MD, Upton C, Narunsky K, Mendoza-Ticona A, Khajenoori S, Gonzales P, Badal-Faesen S, Shenje J, Omoz-Oarhe A, Rouzier V, Garcia-Prats AJ, Demers AM, Naini L, Smith E, Churchyard G, Swindells S, Shah NS, Gupta A, Hesseling AC. High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis. Pediatr Infect Dis J. 2022 May 1;41(5):e194-e202. doi: 10.1097/INF.0000000000003505. PMID: 35239624; PMCID: PMC9007870.
• Mulenga H, Fiore-Gartland A, Mendelsohn SC, Penn-Nicholson A, Mbandi SK, Borate B, Musvosvi M, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS Study Team. The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. EBioMedicine. 2022 Mar;77:103886. doi: 10.1016/j.ebiom.2022.103886. PMID: 35183869; PMCID: PMC8861653.
• Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Sebe M, Edward VA, Rassool M, Ahmed K, Fielding K, Ahidjo BA, Vangu MDT, Churchyard G. Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial. PLoS One. 2022 Feb 4;17(2):e0252097. doi: 10.1371/journal.pone.0252097. PMID: 35120127; PMCID: PMC8815935.
• Singer SN, Ndumnego OC, Kim RS, Ndung'u T, Anastos K, French A, Churchyard G, Paramithiothis E, Kasprowicz VO, Achkar JM. Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIV. EBioMedicine. 2022 Jan;75:103787. doi: 10.1016/j.ebiom.2021.103787. PMID: 34968761; PMCID: PMC8718743.
• Arriaga MB, Araújo-Pereira M, Barreto-Duarte B, Sales C, Miguez-Pinto JP, Nogueira EB, Nogueira BMF, Rocha MS, Souza AB, Benjamin A, de Oliveira JG, Moreira ASR, Queiroz ATL, Rodrigues MMS, Spener-Gomes R, Figueiredo MC, Durovni B, Cavalcante S, Lapa-E-Silva JR, Kritski AL, Cordeiro-Santos M, Sterling TR, Rolla VC, Andrade BB; RePORT-Brazil consortium. Prevalence and Clinical Profiling of Dysglycemia and HIV Infection in Persons With Pulmonary Tuberculosis in Brazil. Front Med (Lausanne). 2022 Jan 21;8:804173. doi: 10.3389/fmed.2021.804173. PMID: 35127760; PMCID: PMC8814308.
• Pietersen E, Anderson K, van der Heijden YF. Public health and hospital-based nursing intersection: Case study of drug-resistant tuberculosis patients. Public Health Nurs. 2022 Jan;39(1):170-179. doi: 10.1111/phn.13042. PMID: 34990027; PMCID: PMC8766955.
• Haas DW, Abdelwahab MT, van Beek SW, Baker P, Maartens G, Bradford Y, Ritchie MD, Wasserman S, Meintjes G, Beeri K, Gandhi NR, Svensson EM, Denti P, Brust JCM. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. J Infect Dis. 2022 Jan 29:jiac024. doi: 10.1093/infdis/jiac024. PMID: 35091749.
• Calderon RI, Arriaga MB, Aliaga JG, Barreda NN, Sanabria OM, Barreto-Duarte B, Franco JPD, Lecca L, Andrade BB, Carvalho ACC, Kritski AL. Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru. Int J Infect Dis. 2022 Jan 13:S1201-9712(22)00013-3. doi: 10.1016/j.ijid.2022.01.012. PMID: 35033658.

2021

• Mulenga H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, Kimbung Mbandi S, Fiore-Gartland A, Tameris M, Mabwe S, Africa H, Bilek N, Kafaar F, Khader SA, Carstens B, Hadley K, Hikuam C, Erasmus M, Jaxa L, Raphela R, Nombida O, Kaskar M, Nicol MP, Mbhele S, Van Heerden J, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Walzl G, Naidoo K, Churchyard G, Hatherill M, Scriba TJ; CORTIS Study Team. Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. Am J Respir Crit Care Med. 2021 Dec 15;204(12):1463-1472. doi: 10.1164/rccm.202103-0548OC. PMID: 34520313.
• Singhania A, Dubelko P, Kuan R, Chronister WD, Muskat K, Das J, Phillips EJ, Mallal SA, Seumois G, Vijayanand P, Sette A, Lerm M, Peters B, Lindestam Arlehamn C. CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature. EBioMedicine. 2021 Dec;74:103746. doi: 10.1016/j.ebiom.2021.103746. PMID: 34902786; PMCID: PMC8671872.
• Costa AG, Carvalho BKS, Araújo-Pereira M, Ibiapina HNS, Spener-Gomes R, Souza AB, Gomes-Silva A, Andrade AMS, Silva EC, Arriaga MB, Benjamin A, Rocha MS, Moreira ASR, Oliveira JG, Figueiredo MC, Turner MM, Durovni B, Cavalcante S, Kritski AL, Rolla VC, Sterling TR, Andrade BB, Cordeiro-Santos M; RePORT-Brazil Consortium. Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil. Microbiol Spectr. 2021 Dec 22;9(3):e0116321. doi: 10.1128/Spectrum.01163-21. PMID: 34851140; PMCID: PMC8635161.
• Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, Marx FM, Meghji J, Pedrazzoli D, Salomon JA, Sweeney S, van Kampen SC, Wallis RS, Houben RMGJ, Cohen T. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Glob Health. 2021 Dec;9(12):e1679-e1687. doi: 10.1016/S2214-109X(21)00367-3. PMID: 34798027; PMCID: PMC8609280.
• Pearlman SI, Tang EM, Tao YK, Haselton FR. Controlling Droplet Marangoni Flows to Improve Microscopy-Based TB Diagnosis. Diagnostics (Basel). 2021 Nov 21;11(11):2155. doi: 10.3390/diagnostics11112155. PMID: 34829502; PMCID: PMC8618690.
• Schwalb A, Cachay R, Meza E, Cáceres T, Blackman A, Maruri F, Sterling TR, Gotuzzo E. Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru. BMC Res Notes. 2021 Nov 14;14(1):413. doi: 10.1186/s13104-021-05832-0. PMID: 34776013; PMCID: PMC8591909.
• Weinberg A, Aaron L, Montepiedra G, Sterling TR, Browning R, Mmbaga B, Vhembo T, Naik S, Kabugho E, Masheto G, Pahwa S, Mathad JS, LaCourse SM, McCarthy K, Bradford S, Theron G, Costello D, Zimmer B, Pierre MF, Gausi K, Denti P, Haas DW, Gupta A; IMPAACT P1078 study team. Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. Clin Infect Dis. 2021 Nov 2;73(9):e3555-e3562. doi: 10.1093/cid/ciaa1083. PMID: 32720695; PMCID: PMC8563205.
• van der Heijden YF, Zhang B, Chougnet CA, Huaman MA. Cytomegalovirus Infection Is Associated With Increased Prevalence of Latent Tuberculosis Infection. Open Forum Infect Dis. 2021 Oct 23;8(11):ofab539. doi: 10.1093/ofid/ofab539. PMID: 35198641; PMCID: PMC8855520.
• Radtke KK, Ernest JP, Zhang N, Ammerman NC, Nuermberger E, Belknap R, Boyd R, Sterling TR, Savic RM. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0170521. doi: 10.1128/AAC.01705-21. PMID: 34606336; PMCID: PMC8597776.
• Gupte AN, Kumar P, Araújo-Pereira M, Kulkarni V, Paradkar M, Pradhan N, Menon P, Chandrasekaran PD, Hanna LE, Yogendra Shivakumar SVB, Rockwood N, Du Bruyn E, Karyakarte R, Gaikwad S, Bollinger R, Golub J, Gupte N, Viswanathan V, Wilkinson RJ, Mave V, Babu S, Kornfeld H, Andrade BB, Gupta A. Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study. Eur Respir J. 2021 Oct 28:2100905. doi: 10.1183/13993003.00905-2021. PMID: 34711538.
• Arriaga MB, Araújo-Pereira M, Barreto-Duarte B, Nogueira B, Freire MVCNS, Queiroz ATL, Rodrigues MMS, Rocha MS, Souza AB, Spener-Gomes R, Carvalho ACC, Figueiredo MC, Turner MM, Durovni B, Lapa-E-Silva JR, Kritski AL, Cavalcante S, Rolla VC, Cordeiro-Santos M, Sterling TR, Andrade BB; RePORT Brazil consortium. The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes: A Multi-center Prospective Cohort Study. J Infect Dis. 2021 Oct 15:jiab427. doi: 10.1093/infdis/jiab427. PMID: 34651642.
• Tibúrcio R, Barreto-Duarte B, Naredren G, Queiroz ATL, Anbalagan S, Nayak K, Ravichandran N, Subramani R, Antonelli LRV, Satagopan K, Anbalagan K, Porter BO, Sher A, Swaminathan S, Sereti I, Andrade BB. Dynamics of T-Lymphocyte Activation Related to Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in Persons With Advanced HIV. Front Immunol. 2021 Oct 7;12:757843. doi: 10.3389/fimmu.2021.757843. PMID: 34691079; PMCID: PMC8529328.
• Souza AB, Arriaga MB, Amorim G, Araújo-Pereira M, Nogueira BMF, Queiroz ATL, Figueiredo MC, Rocha MS, Benjamin A, Moreira ASR, Oliveira JG, Rolla V, Durovni B, Lapa E Silva JR, Kritski AL, Cavalcante S, Sterling T, Andrade BB, Cordeiro-Santos M; RePORT Brazil consortium. Determinants of losses in the latent tuberculosis infection cascade of care in Brazil. BMJ Glob Health. 2021 Sep;6(9):e005969. doi: 10.1136/bmjgh-2021-005969. PMID: 34518204.
• Churchyard G, Cárdenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, Martinson N, Yimer G, Wang SH, Garcia-Basteiro AL, Nguenha D, Masilela L, Waggie Z, van den Hof S, Charalambous S, Cobelens F, Chaisson RE, Grant AD, Fielding KL; WHIP3TB Study Team. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection: A Randomized Trial. Ann Intern Med. 2021 Aug 24. doi: 10.7326/M20-7577. PMID: 34424730.
• Bohrer AC, Castro E, Hu Z, Queiroz ATL, Tocheny CE, Assmann M, Sakai S, Nelson C, Baker PJ, Ma H, Wang L, Zilu W, du Bruyn E, Riou C, Kauffman KD; Tuberculosis Imaging Program, Moore IN, Del Nonno F, Petrone L, Goletti D, Martineau AR, Lowe DM, Cronan MR, Wilkinson RJ, Barry CE, Via LE, Barber DL, Klion AD, Andrade BB, Song Y, Wong KW, Mayer-Barber KD. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. J Exp Med. 2021 Oct 4;218(10):e20210469. doi: 10.1084/jem.20210469. PMID: 34347010; PMCID: PMC8348215.
• Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Edward VA, Rassool M, Ahmed K, Fielding K, Ahidjo BA, Vangu MDT, Churchyard G. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021 Aug;9(8):897-908. doi: 10.1016/S2213-2600(20)30448-3. PMID: 33740465; PMCID: PMC8332197.
• Haas DW, Mngqibisa R, Francis J, McIlleron H, Robinson JA, Kendall MA, Baker P, Mawlana S, Badal-Faesen S, Angira F, Omoz-Oarhe A, Samaneka WP, Denti P, Cohn SE; AIDS Clinical Trials Group A5338 Study Team. Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenet Genomics. 2021 Aug 6. doi: 10.1097/FPC.0000000000000448. PMID: 34369424.
• Bruyn ED, Fukutani KF, Rockwood N, Schutz C, Meintjes G, Arriaga MB, Cubillos-Angulo JM, Tibúrcio R, Sher A, Riou C, Wilkinson KA, Andrade BB, Wilkinson RJ. Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis. Lancet Microbe. 2021 Aug;2(8):e375-e385. doi: 10.1016/S2666-5247(21)00037-9. PMID: 34386782; PMCID: PMC8357308.
• Montepiedra G, Kim S, Weinberg A, Theron G, Sterling TR, LaCourse SM, Bradford S, Chakhtoura N, Jean-Philippe P, Evans S, Gupta A. Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. Clin Infect Dis. 2021 Aug 2;73(3):e587-e593. doi: 10.1093/cid/ciaa1674. PMID: 33146706; PMCID: PMC8326545.
• Moodley N, Velen K, Saimen A, Zakhura N, Churchyard G, Charalambous S. Digital chest radiography enhances screening efficiency for pulmonary tuberculosis in primary health clinics, South Africa. Clin Infect Dis. 2021 Jul 27:ciab644. doi: 10.1093/cid/ciab644. PMID: 34313729.
• Barreto-Duarte B, Araújo-Pereira M, Nogueira BMF, Sobral L, Rodrigues MMS, Queiroz ATL, Rocha MS, Nascimento V, Souza AB, Cordeiro-Santos M, Kritski AL, Sterling TR, Arriaga MB, Andrade BB. Tuberculosis Burden and Determinants of Treatment Outcomes According to Age in Brazil: A Nationwide Study of 896,314 Cases Reported Between 2010 and 2019. Front Med (Lausanne). 2021 Jul 27;8:706689. doi: 10.3389/fmed.2021.706689. PMID: 34386510; PMCID: PMC8354381.
• Simmons JD, Van PT, Stein CM, Chihota V, Ntshiqa T, Maenetje P, Peterson GJ, Reynolds A, Benchek P, Velen K, Fielding KL, Grant AD, Graustein AD, Nguyen FK, Seshadri C, Gottardo R, Mayanja-Kizza H, Wallis RS, Churchyard G, Boom WH, Hawn TR. Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-γ release assay conversion. J Clin Invest. 2021 Jul 15;131(14):e140073. doi: 10.1172/JCI140073. PMID: 34111032; PMCID: PMC8279582.
• Carvalho ACC, Amorim G, Melo MGM, Silveira AKA, Vargas PHL, Moreira ASR, Rocha MS, Souza AB, Arriaga MB, Araújo-Pereira M, Figueiredo MC, Durovni B, Lapa-E-Silva JR, Cavalcante S, Rolla VC, Sterling TR, Cordeiro-Santos M, Andrade BB, Silva EC, Kritski AL; RePORT Brazil consortium. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Front Immunol. 2021 Jul 2;12:661934. doi: 10.3389/fimmu.2021.661934. PMID: 34276654; PMCID: PMC8284392.
• Peetluk LS, Rebeiro PF, Ridolfi FM, Andrade BB, Cordeiro-Santos M, Kritski A, Durovni B, Cavalcante S, Figueiredo MC, Haas DW, Liu D, Rolla VC, Sterling TR; RePORT-Brazil network. A clinical prediction model for unsuccessful pulmonary tuberculosis treatment outcomes. Clin Infect Dis. 2021 Jul 2:ciab598. doi: 10.1093/cid/ciab598. PMID: 34214166.
• Costa DL, Amaral EP, Namasivayam S, Mittereder LR, Andrade BB, Sher A. Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work? Front Cell Infect Microbiol. 2021 Jun 21;11:672527. doi: 10.3389/fcimb.2021.672527. PMID: 34235093; PMCID: PMC8256258.
• Cubillos-Angulo JM, Fernandes CD, Araújo DN, Carmo CA, Arriaga MB, Andrade BB. The influence of single nucleotide polymorphisms of NOD2 or CD14 on the risk of Mycobacterium tuberculosis diseases: a systematic review. Syst Rev. 2021 Jun 9;10(1):174. doi: 10.1186/s13643-021-01729-y. PMID: 34108050; PMCID: PMC8191055.
• Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, Hadley K, Hikuam C, Musvosvi M, Bilek N, Erasmus M, Jaxa L, Raphela R, Nombida O, Kaskar M, Sumner T, White RG, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS-HR Study Team. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. Lancet Glob Health. 2021 Jun;9(6):e841-e853. doi: 10.1016/S2214-109X(21)00045-0. PMID: 33862012; PMCID: PMC8131200.
• Krishnan S, Queiroz ATL, Gupta A, Gupte N, Bisson GP, Kumwenda J, Naidoo K, Mohapi L, Mave V, Mngqibisa R, Lama JR, Hosseinipour MC, Andrade BB, Karakousis PC. Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV. Front Immunol. 2021 Jun 8;12:676980. doi: 10.3389/fimmu.2021.676980. PMID: 34168648; PMCID: PMC8217878.
• Shivakoti R, Newman JW, Hanna LE, Queiroz ATL, Borkowski K, Gupte AN, Paradkar M, Satyamurthi P, Kulkarni V, Selva M, Pradhan N, Shivakumar SVBY, Natarajan S, Karunaianantham R, Gupte N, Thiruvengadam K, Fiehn O, Bharadwaj R, Kagal A, Gaikwad S, Sangle S, Golub JE, Andrade BB, Mave V, Gupta A, Padmapriyadarsini C. Host Lipidome and Tuberculosis Treatment Failure. Eur Respir J. 2021 Jun 17:2004532. doi: 10.1183/13993003.04532-2020. PMID: 34375300.
• Ley SD, Pillay S, Streicher EM, van der Heijden YF, Sirgel F, Derendinger B, de Kock M, Gagneux S, Warren RM, Theron G, de Vos M. Melting the eis: Nondetection of Kanamycin Resistance Markers by Routine Diagnostic Tests and Identification of New eis Promoter Variants. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0250220. doi: 10.1128/AAC.02502-20. PMID: 33903113; PMCID: PMC8218670.
• Maruri F, Guo Y, Blackman A, van der Heijden YF, Rebeiro PF, Sterling TR. Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance. Clin Infect Dis. 2021 Jun 1;72(11):1910-1918. doi: 10.1093/cid/ciaa496. PMID: 32348473; PMCID: PMC8315129.
• Arriaga MB, Rocha MS, Nogueira B, Nascimento V, Araújo-Pereira M, Souza AB, Andrade AMS, Costa AG, Gomes-Silva A, Silva EC, Figueiredo MC, Turner MM, Durovni B, Lapa-E-Silva JR, Kritski AL, Cavalcante S, Rolla VC, Cordeiro-Santos M, Sterling TR, Andrade BB; RePORT Brazil consortium. The Effect of Diabetes and Prediabetes on Mycobacterium tuberculosis Transmission to Close Contacts. J Infect Dis. 2021 May 19:jiab264. doi: 10.1093/infdis/jiab264. PMID: 34008010.
• Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. PMID: 33951360; PMCID: PMC8282329.
• Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T, Haas DW, Browning R, Chakhtoura N, Montepiedra G, Aaron L, McCarthy K, Bradford S, Vhembo T, Stranix-Chibanda L, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Nevrekhar N, Rouzier V, Kabugho E, Mutambanengwe M, Chanaiwa V, Nyati M, Mhembere T, Tongprasert F, Hesseling A, Shin K, Zimmer B, Costello D, Jean-Philippe P, Sterling TR, Theron G, Weinberg A, Gupta A, Denti P; IMPAACT P1078 (TB APPRISE) Study Group Team. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping . Clin Pharmacol Ther. 2021 Apr;109(4):1034–1044. doi: 10.1002/cpt.2044.
• Vinhaes CL, Sheikh V, Oliveira-de-Souza D, Wang J, Rupert A, Roby G, Arriaga MB, Fukutani KF, Sawe F, Shaffer D, Ananworanich J, Phanuphak N, Andrade BB, Sereti I. An Inflammatory Composite Score Predicts Mycobacterial Immune Reconstitution Inflammatory Syndrome in People with Advanced HIV: A Prospective International Cohort Study . J Infect Dis. 2021 Apr 8;223(7):1275–1283. doi: 10.1093/infdis/jiaa484.
• Oleaga-Quintas C, de Oliveira-Júnior EB, Rosain J, Rapaport F, Deswarte C, Guérin A, Sajjath SM, Zhou YJ, Marot S, Lozano C, Branco L, Fernández-Hidalgo N, Lew DB, Brunel AS, Thomas C, Launay E, Arias AA, Cuffel A, Monjo VC, Neehus AL, Marques L, Roynard M, Moncada-Vélez M, Gerçeker B, Colobran R, Vigué MG, Lopez-Herrera G, Berron-Ruiz L, Méndez NHS, O'Farrill Romanillos P, Le Voyer T, Puel A, Bellanné-Chantelot C, Ramirez KA, Lorenzo-Diaz L, Alejo NR, de Diego RP, Condino-Neto A, Mellouli F, Rodriguez-Gallego C, Witte T, Restrepo JF, Jobim M, Boisson-Dupuis S, Jeziorski E, Fieschi C, Vogt G, Donadieu J, Pasquet M, Vasconcelos J, Ardeniz FO, Martínez-Gallo M, Campos RA, Jobim LF, Martínez-Barricarte R, Liu K, Cobat A, Abel L, Casanova JL, Bustamante J. Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance . J Clin Immunol. 2021 Apr;41(3):639–657. doi: 10.1007/s10875-020-00930-3.
• Baliashvili D, Gandhi NR, Kim S, Hughes M, Mave V, Mendoza-Ticona A, Gonzales P, Kim N, Selvamuthu P, Badal-Faesen S, Upton C, Naini L, Smith E, Gupta A, Churchyard G, Swindells S, Hesseling A, Shah NS. Resistance to Mycobacterium tuberculosis infection among household contacts: a multinational study . Clin Infect Dis. 2021 Mar 27. doi: 10.1093/cid/ciab269.
• Manesen R, Mekler KA, Molobi TR, Tyiki AA, Madlavu MJ, Velen K, Charalambous S, van der Heijden YF. Data quality assessment of a South African electronic registry for drug-resistant TB, 2015–2016 . Public Health Action. 2021 Mar 21;11(1):33–39. doi: 10.5588/pha.20.0031. PMID: 33777719; PMCID: PMC7987250
• Spener-Gomes R, Costa AG, de Melo HF, de Souza AB, Beraldi-Magalhães F, Jesus JS, Arriaga MB, Kritski A, Safe I, Andrade BB, Trajman A, Cordeiro-Santos M. Examination of respiratory specimens improves microbiological diagnosis of patients with presumptive extrapulmonary tuberculosis . Int J Infect Dis. 2021 Mar 12. doi: 10.1016/j.ijid.2021.03.022.
• Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, Mendelsohn SC, Hadley K, Hikuam C, Kaskar M, Musvosvi M, Bilek N, Self S, Sumner T, White RG, Erasmus M, Jaxa L, Raphela R, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M; CORTIS-01 Study Team. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial . Lancet Infect Dis. 2021 Mar;21(3):354–365. doi: 10.1016/S1473-3099(20)30914-2.
• Peetluk LS, Ridolfi FM, Rebeiro PF, Liu D, Rolla VC, Sterling TR. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults . BMJ Open. 2021 Mar 2;11(3):e044687. doi: 10.1136/bmjopen-2020-044687.
• Demers AM, Kim S, McCallum S, Eisenach K, Hughes M, Naini L, Mendoza-Ticona A, Pradhan N, Narunsky K, Poongulali S, Badal-Faesen S, Upton C, Smith E, Shah NS, Churchyard G, Gupta A, Hesseling A, Swindells S; ACTG A5300/IMPAACT I2003 PHOENIx Feasibility Study Team. Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial . BMC Infect Dis. 2021 Feb 24;21(1):205. doi: 10.1186/s12879-021-05884-4.
• Kulkarni V, Queiroz ATL, Sangle S, Kagal A, Salvi S, Gupta A, Ellner J, Kadam D, Rolla VC, Andrade BB, Salgame P, Mave V. A Two-Gene Signature for Tuberculosis Diagnosis in Persons With Advanced HIV . Front Immunol. 2021 Feb 22;12:631165. doi: 10.3389/fimmu.2021.631165.
• van der Horst M, Karamchand L, Bauer WS, Nel AJM, Blackburn JM, Wright DW. The cyanobacterial lectin, microvirin-N, enhances the specificity and sensitivity of lipoarabinomannan-based TB diagnostic tests . Analyst. 2021 Feb 21;146(4):1207–1215. doi: 10.1039/d0an01725f.
• Amaral EP, Vinhaes CL, Oliveira-de-Souza D, Nogueira B, Akrami KM, Andrade BB. The Interplay Between Systemic Inflammation, Oxidative Stress, and Tissue Remodeling in Tuberculosis . Antioxid Redox Signal. 2021 Feb 20;34(6):471–485. doi: 10.1089/ars.2020.8124.
• Blackman A, Morrison B, Maruri F, van der Heijden Y, Nochowicz CH, Guo Y, Scholz M, Rustad T, Sherman DR, Sterling TR. Re-evaluation of a novel resistance mutation in eccC5 of the ESX-5 secretion system in ofloxacin-resistant Mycobacterium tuberculosis . J Antimicrob Chemother. 2021 Feb 11;76(3):820–822. doi: 10.1093/jac/dkaa507.
• Safe IP, Amaral EP, Araújo-Pereira M, Lacerda MVG, Printes VS, Souza AB, Beraldi-Magalhães F, Monteiro WM, Sampaio VS, Barreto-Duarte B, Andrade AMS, Spener-Gomes R, Costa AG, Cordeiro-Santos M, Andrade BB. Adjunct N-Acetylcysteine Treatment in Hospitalized Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood . Front Immunol. 2021 Feb 4;11:602589. doi: 10.3389/fimmu.2020.602589.
• Haas DW, Podany AT, Bao Y, Swindells S, Chaisson RE, Mwelase N, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Baker P, Fletcher CV. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine . Pharmacogenet Genomics. 2021 Jan;31(1):17–27. doi: 10.1097/FPC.0000000000000417.
• Naik S, Alexander M, Kumar P, Kulkarni V, Deshpande P, Yadana S, Leu CS, Araújo-Pereira M, Andrade BB, Bhosale R, Babu S, Gupta A, Mathad JS, Shivakoti R. Systemic Inflammation in Pregnant Women With Latent Tuberculosis Infection . Front Immunol. 2021 Jan 27;11:587617. doi: 10.3389/fimmu.2020.587617. PMID: 33584652; PMCID: PMC7873478
• Gupte AN, Selvaraju S, Gaikwad S, Mave V, Kumar P, Babu S, Andrade BB, Checkley W, Bollinger R, Gupta A. Higher interleukin-6 levels and changes in transforming growth factor-β are associated with lung impairment in pulmonary tuberculosis . ERJ Open Res. 2021 Jan 18;7(1):00390-2020. doi: 10.1183/23120541.00390-2020.
• Costa DL, Amaral EP, Namasivayam S, Mittereder LR, Fisher L, Bonfim CC, Sardinha-Silva A, Thompson RW, Hieny SE, Andrade BB, Sher A. Heme oxygenase-1 inhibition promotes IFNγ- and NOS2-mediated control of Mycobacterium tuberculosis infection . Mucosal Immunol. 2021 Jan;14(1):253–266. doi: 10.1038/s41385-020-00342-x.
• Auld SC, Kornfeld H, Maenetje P, Mlotshwa M, Chase W, Vangu MD, Torigian DA, Wallis RS, Churchyard G, Bisson GP. Pulmonary restriction predicts long-term pulmonary impairment in people with HIV and tuberculosis . BMC Pulm Med. 2021 Jan 7;21(1):19. doi: 10.1186/s12890-020-01368-4.
• Huaman MA, De Cecco CN, Bittencourt MS, Ticona E, Kityo C, Ballena I, Nalukwago S, Nazzinda R, Ticona C, Azañero R, Zhang B, Farquhar C, Hawn TR, Sterling TR, Fichtenbaum CJ, Longenecker CT. Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda . Clin Infect Dis. 2021 Jan 3. doi: 10.1093/cid/ciaa1934. Epub ahead of print. PMID: 33388766

2020

• Barreto-Duarte B, Sterling TR, Fiske CT, Almeida A, Nochowicz CH, Smith RM, Barnett L, Warren C, Blackman A, Lapa E Silva JR, Andrade BB, Kalams SA. Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis . Front Immunol. 2020 Dec 17;11:605338. doi: 10.3389/fimmu.2020.605338.
• Manabe YC, Andrade BB, Gupte N, Leong S, Kintali M, Matoga M, Riviere C, Samaneka W, Lama JR, Naidoo K, Zhao Y, Johnson WE, Ellner JJ, Hosseinipour MC, Bisson GP, Salgame P, Gupta A. A Parsimonious Host Inflammatory Biomarker Signature Predicts Incident Tuberculosis and Mortality in Advanced Human Immunodeficiency Virus . Clin Infect Dis. 2020 Dec 17;71(10):2645–2654. doi: 10.1093/cid/ciz1147.
• Arriaga MB, Amorim G, Queiroz ATL, Rodrigues MMS, Araújo-Pereira M, Nogueira BMF, Souza AB, Rocha MS, Benjamin A, Moreira ASR, de Oliveira JG, Figueiredo MC, Turner MM, Alves K, Durovni B, Lapa-E-Silva JR, Kritski AL, Cavalcante S, Rolla VC, Cordeiro-Santos M, Sterling TR, Andrade BB. Novel Stepwise Approach to Assess Representativeness of a Large Multicenter Observational Cohort of Tuberculosis Patients: The Example of RePORT Brazil . Int J Infect Dis. 2020 Nov. doi: 10.1016/j.ijid.2020.11.140.
• Dutta NK, Tornheim JA, Fukutani KF, Paradkar M, Tiburcio RT, Kinikar A, Valvi C, Kulkarni V, Pradhan N, Shivakumar SVBY, Kagal A, Gupte A, Gupte N, Mave V, Gupta A, Andrade BB, Karakousis PC. Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children . Sci Rep. 2020 Nov 11;10(1):19527. doi: 10.1038/s41598-020-75513-8.
• Silveira-Mattos PS, Barreto-Duarte B, Vasconcelos B, Fukutani KF, Vinhaes CL, Oliveira-De-Souza D, Ibegbu CC, Figueiredo MC, Sterling TR, Rengarajan J, Andrade BB. Differential Expression of Activation Markers by Mycobacterium tuberculosis-specific CD4+ T Cell Distinguishes Extrapulmonary From Pulmonary Tuberculosis and Latent Infection . Clin Infect Dis. 2020 Nov 5;71(8):1905–1911. doi: 10.1093/cid/ciz1070.
• Montepiedra G, Kim S, Weinberg A, Theron G, Sterling TR, LaCourse SM, Bradford S, Chakhtoura N, Jean-Philippe P, Evans S, Gupta A. Using a composite maternal-infant outcome measure in tuberculosis prevention studies among pregnant women . Clin Infect Dis. 2020 Nov. doi: 10.1093/cid/ciaa1674.
• Reichler MR, Khan A, Yuan Y, Chen B, McAuley J, Mangura B, Sterling TR. Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection . Clin Infect Dis. 2020 Oct 23;71(7):1627–1634. doi: 10.1093/cid/ciz1044.
• Sterling TR, Lin PL. Treatment of latent M. tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis . J Clin Invest. 2020 Oct 1;130(10):5102–5104. doi: 10.1172/JCI137294.
• Merrikh H, Kohli RM. Targeting evolution to inhibit antibiotic resistance . FEBS J. 2020 Oct;287(20):4341–4353. doi: 10.1111/febs.15370.
• Demitto FO, Araújo-Pereira M, Schmaltz CA, Sant'Anna FM, Arriaga MB, Andrade BB, Rolla VC. Impact of Persistent Anemia on Systemic Inflammation and Tuberculosis Outcomes in Persons Living With HIV . Front Immunol. 2020 Sep 24;11:588405. doi: 10.3389/fimmu.2020.588405.
• Narendran G, Jyotheeswaran K, Senguttuvan T, Vinhaes CL, Santhanakrishnan RK, Manoharan T, Selvaraj A, Chandrasekaran P, Menon PA, Bhavani KP, Reddy D, Narayanan R, Subramanyam B, Sathyavelu S, Krishnaraja R, Kalirajan P, Angamuthu D, Susaimuthu SM, Ganesan RRK, Tripathy SP, Swaminathan S, Andrade BB. Characteristics of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and its influence on tuberculosis treatment outcomes in persons living with HIV . Int J Infect Dis. 2020 Sep;98:261–267. doi: 10.1016/j.ijid.2020.06.097.
• Ndlovu LN, Peetluk L, Moodley S, Nhamoyebonde S, Ngoepe AT, Mazibuko M, Khan K, Karim F, Pym AS, Maruri F, Moosa MS, van der Heijden YF, Sterling TR, Leslie A. Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection . Front Immunol. 2020 Aug 28;11:1872. doi: 10.3389/fimmu.2020.01872.
• Manful A, Waller L, Katz B, Cummins J, Warkentin J, Reagon B, Shaw-Kaikai J, Zhu Y, van der Heijden YF. Gaps in the care cascade for screening and treatment of refugees with tuberculosis infection in Middle Tennessee: a retrospective cohort study . BMC Infect Dis. 2020 Aug 10;20(1):592. doi: 10.1186/s12879-020-05311-0.
• Pettit AC, Stout JE, Belknap R, Benson CA, Séraphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS. Optimal testing choice and diagnostic strategies for latent tuberculosis infection among U.S.-born people living with HIV . Clin Infect Dis. 2020 Aug 6. doi: 10.1093/cid/ciaa1135.
• Reichler MR, Hirsch C, Yuan Y, Khan A, Dorman SE, Schluger N, Sterling TR. Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada . BMC Infect Dis. 2020 Jul 31;20(1):553. doi: 10.1186/s12879-020-05185-2.
• Weinberg A, Aaron L, Montepiedra G, Sterling TR, Browning R, Mmbaga B, Vhembo T, Naik S, Kabugho E, Masheto G, Pahwa S, Mathad JS, LaCourse SM, McCarthy K, Bradford S, Theron G, Costello D, Zimmer B, Pierre MF, Gausi K, Denti P, Haas DW, Gupta A. Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV . Clin Infect Dis. 2020 Jul 28. doi: 10.1093/cid/ciaa1083.
• Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection . Am J Respir Crit Care Med. 2020 Jul 15;202(2):305–306. doi: 10.1164/rccm.202003-0855LE.
• Oliveira-de-Souza D, Vinhaes CL, Arriaga MB, Kumar NP, Queiroz ATL, Fukutani KF, Babu S, Andrade BB. Aging increases the systemic molecular degree of inflammatory perturbation in patients with tuberculosis . Sci Rep. 2020 Jul 9;10(1):11358. doi: 10.1038/s41598-020-68255-0.
• Safe IP, Lacerda MVG, Printes VS, Praia Marins AF, Rebelo Rabelo AL, Costa AA, Tavares MA, Jesus JS, Souza AB, Beraldi-Magalhães F, Neves CP, Monteiro WM, Sampaio VS, Amaral EP, Gomes RS, Andrade BB, Cordeiro-Santos M. Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study) . PLoS One. 2020 Jun 26;15(6):e0235381. doi: 10.1371/journal.pone.0235381.
• Koenig SP, Kim A, Shepherd BE, Cesar C, Veloso V, Cortes CP, Padgett D, Crabtree-Ramírez B, Gotuzzo E, McGowan CC, Sterling TR, Pape JW. Increased Mortality After Tuberculosis Treatment Completion in Persons Living With Human Immunodeficiency Virus in Latin America . Clin Infect Dis. 2020 Jun 24;71(1):215–217. doi: 10.1093/cid/ciz1032.
• Rebeiro PF, Cohen MJ, Ewing HM, Figueiredo MC, Peetluk LS, Andrade KB, Eakin M, Zechmeister EJ, Sterling TR. Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies . BMC Public Health. 2020 Jun 9;20(1):897. doi: 10.1186/s12889-020-09053-1.
• Kerner G, Rosain J, Guérin A, Al-Khabaz A, Oleaga-Quintas C, Rapaport F, Massaad MJ, Ding JY, Khan T, Ali FA, Rahman M, Deswarte C, Martinez-Barricarte R, Geha RS, Jeanne-Julien V, Garcia D, Chi CY, Yang R, Roynard M, Fleckenstein B, Rozenberg F, Boisson-Dupuis S, Ku CL, Seeleuthner Y, Béziat V, Marr N, Abel L, Al-Herz W, Casanova JL, Bustamante J. Inherited human IFN-γ deficiency underlies mycobacterial disease . J Clin Invest. 2020 Jun 1;130(6):3158–3171. doi: 10.1172/JCI135460.
• Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM. Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection . J Clin Microbiol. 2020 May 26;58(6):e00393-20. doi: 10.1128/JCM.00393-20.
• Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, Malherbe ST, Darboe F, Erasmus M, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Winter J, Murphy M, Wood R, Morrow C, Van Rhijn I, Moody B, Murray M, Andrade BB, Sterling TR, Sutherland J, Naidoo K, Padayatchi N, Walzl G, Hatherill M, Zak D, Scriba TJ. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response . Sci Rep. 2020 May 25;10(1):8629. doi: 10.1038/s41598-020-65043-8.
• Herricks T, Donczew M, Mast FD, Rustad T, Morrison R, Sterling TR, Sherman DR, Aitchison JD. ODELAM, rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis . Elife. 2020 May 13;9:e56613. doi: 10.7554/eLife.56613.
• Maruri F, Guo Y, Blackman A, van der Heijden YF, Rebeiro PF, Sterling TR. Resistance-conferring mutations on whole-genome sequencing of fluoroquinolone-resistant and -susceptible M. tuberculosis isolates: a proposed threshold for identifying resistance . Clin Infect Dis. 2020 Apr. doi: 10.1093/cid/ciaa496.
• Tornheim JA, Madugundu AK, Paradkar M, Fukutani KF, Queiroz ATL, Gupte N, Gupte AN, Kinikar A, Kulkarni V, Balasubramanian U, Sreenivasamurthy S, Raja R, Pradhan N, Shivakumar SVBY, Valvi C, Hanna LE, Andrade BB, Mave V, Pandey A, Gupta A. Transcriptomic Profiles of Confirmed Pediatric Tuberculosis Patients and Household Contacts Identifies Active Tuberculosis, Infection, and Treatment Response Among Indian Children . J Infect Dis. 2020 Apr 27;221(10):1647–1658. doi: 10.1093/infdis/jiz639.
• Reichler MR, Khan A, Sterling TR, Zhao H, Chen B, Yuan Y, Moran J, McAuley J, Mangura B. Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons With Infectious Tuberculosis . Clin Infect Dis. 2020 Apr 10;70(8):1562–1572. doi: 10.1093/cid/ciz438.
• Peetluk LS, Rebeiro PF, Cordeiro-Santos M, Kritski A, Andrade BB, Durovni B, Calvacante S, Arriaga MB, Turner MM, Figueiredo MC, Rolla VC, Sterling TR. Lack of weight gain during the first two months of treatment and HIV independently predict unsuccessful treatment outcomes in tuberculosis . J Infect Dis. 2020 Apr 7;221(9):1416–1424. doi: 10.1093/infdis/jiz595.
• Araújo NCN, Cruz CMS, Arriaga MB, Cubillos-Angulo JM, Rocha MS, Silveira-Mattos PS, Matos GM, Marques IMB, Espirito Santo ICP, Almeida LL, Andrade CM, Souza LA, Netto EM, Andrade BB. Determinants of losses in the latent tuberculosis cascade of care in Brazil: A retrospective cohort study . Int J Infect Dis. 2020 Apr;93:277–283. doi: 10.1016/j.ijid.2020.02.015.
• Shivakoti R, Dalli J, Kadam D, Gaikwad S, Barthwal M, Colas RA, Mazzacuva F, Lokhande R, Dharmshale S, Bharadwaj R, Kagal A, Pradhan N, Deshmukh S, Atre S, Sahasrabudhe T, Kakrani A, Kulkarni V, Raskar S, Suryavanshi N, Chon S, Gupte A, Gupta A, Gupte N, Arriaga MB, Fukutani KF, Andrade BB, Golub JE, Mave V. Lipid mediators of inflammation and resolution in individuals with tuberculosis and tuberculosis-diabetes . Prostaglandins Other Lipid Mediat. 2020 Apr;147:106398. doi: 10.1016/j.prostaglandins.2019.106398.
• Nacarapa E, Muchiri E, Moon TD, Charalambous S, Verdu ME, Ramos JM, Valverde EJ. Effect of Xpert MTB/RIF testing introduction and favorable outcome predictors for tuberculosis treatment among HIV infected adults in rural southern Mozambique . PLoS One. 2020 Mar 9;15(3):e0229995. doi: 10.1371/journal.pone.0229995.
• Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling . Am J Respir Crit Care Med. 2020 Mar 1;201(5):598–605. doi: 10.1164/rccm.201908-1606OC.
• Cubillos-Angulo JM, Arriaga MB, Melo MGM, Silva EC, Alvarado-Arnez LE, de Almeida AS, Moraes MO, Moreira ASR, Lapa E Silva JR, Fukutani KF, Sterling TR, Hawn TR, Kritski AL, Oliveira MM, Andrade BB. Polymorphisms in interferon pathway genes and risk of Mycobacterium tuberculosis infection in contacts of tuberculosis cases in Brazil . Int J Infect Dis. 2020 Mar;92:21–28. doi: 10.1016/j.ijid.2019.12.013.
• Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial . Contemp Clin Trials. 2020 Mar;90:105938. doi: 10.1016/j.cct.2020.105938.
• Barreda NN, Arriaga MB, Aliaga JG, Lopez K, Sanabria OM, Carmo TA, Fróes Neto JF, Lecca L, Andrade BB, Calderon RI. Severe pulmonary radiological manifestations are associated with a distinct biochemical profile in blood of tuberculosis patients with dysglycemia . BMC Infect Dis. 2020 Feb 14;20(1):139. doi: 10.1186/s12879-020-4843-0.
• Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 . MMWR Recomm Rep. 2020 Feb 14;69(1):1–11. doi: 10.15585/mmwr.rr6901a1.
• Humphrey JM, Mpofu P, Pettit AC, Musick B, Carter EJ, Messou E, Marcy O, Crabtree-Ramirez B, Yotebieng M, Anastos K, Sterling TR, Yiannoutsos C, Diero L, Wools-Kaloustian K. Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis . Open Forum Infect Dis. 2020 Jan 10;7(1):ofaa006. doi: 10.1093/ofid/ofaa006. PMID: 32010735; PMCID: PMC6984675